The use of the tyrosine kinase inhibitor Nilotinib in Spondyloarthritis: does targeting inflammatory pathways with a treatment lead to vascular toxicity?

The use of the tyrosine kinase inhibitor Nilotinib in Spondyloarthritis: does targeting inflammatory pathways with a treatment lead to vascular toxicity?

Abstract Spondylarthritis (SpA) is an inflammatory rheumatic disease associated with increased incidence of major adverse cardiovascular events (MACEs). Recently, Paramarta et al. proposed the use of the tyrosine kinase inhibitor Nilotinib in Spondyloarthritis to target certain inflammatory pathways...

Full description

Bibliographic Details
Main Authors: Loukman Omarjee, Vincent Jaquinandi, Guillaume Mahe
Format: Article
Language:English
Published: BMC 2017-12-01
Series:Journal of Translational Medicine
Subjects:
Spondyloarthritis
Nilotinib
Tyrosine kinase inhibitor
Vascular toxicity
Major adverse cardiovascular events
Peripheral artery disease
Online Access:http://link.springer.com/article/10.1186/s12967-017-1334-1

Internet

http://link.springer.com/article/10.1186/s12967-017-1334-1

Similar Items